CIENCIASMEDICASNEWS

martes, 17 de febrero de 2026

Swallowing development in infants and toddlers with spinal muscular atrophy following therapy compared to healthy controls: the prospective controlled DySMA trial Jana ZangCharlotte DumitrascuJessika Johannsen

https://link.springer.com/journal/13023?utm_source=bmc_etoc&utm_medium=email&utm_campaign=CONR_13023_AWA1_GL_DTEC_054CI_TOC-260214

Post-Traumatic Stress Disorder and Alcohol Consumption: Biological Mechanisms of Stress Resilience to Subsequent Alcohol Consumption Quilla C. Flanagan-Burt,* Celia Middleton,* and Junghyup Suh

https://arcr.niaaa.nih.gov/volume/46/1/post-traumatic-stress-disorder-and-alcohol-consumption-biological-mechanisms-stress?utm_source=arcr-email&utm_medium=email&utm_campaign=suh-2026-02&utm_content=arcr-listserv PURPOSE: Resilience is crucial in mitigating the risk of stress-related health issues. Although many people can adapt to adverse stress or trauma, stress exposure can increase the risk of health issues, including obesity, cardiovascular disease, and digestive illnesses. Some individuals may even develop debilitating conditions, such as post-traumatic stress disorder (PTSD). People with PTSD often struggle to adapt, sometimes turning to alcohol to cope, which can lead to alcohol use disorder (AUD), characterized by excessive alcohol-seeking and dependence. Understanding the biological underpinnings of resilience, therefore, is a key to preventing both PTSD and AUD. Recent research has uncovered the neurobiological traits that protect against the development of stress-induced alcohol dependence. Studies have shown that proactive coping and a lack of stress-related symptoms are associated with resilience. Preclinical studies, especially in rodents, have provided deeper insights into how stress impacts alcohol-seeking behaviors. Research has shown that resilience involves adaptive changes at the molecular, cellular, neural circuit, and systems levels. This review aims to integrate this research to better understand what makes people vulnerable to stress and alcohol consumption, highlighting aspects frequently overlooked in clinical models.

Introducing the CAHPS End-of-Life Care Survey (Webcast) January 15, 2026

https://www.ahrq.gov/cahps/news-and-events/events/webinar-end-of-life-survey-011526.html This webcast explored the purpose and development of AHRQ’s newest Consumer Assessment of Healthcare Providers and Systems (CAHPS®) End-of-Life Care Survey. Experts discussed why this new survey was created, how it was tested, and the best practices for its implementation. The session also featured insights from Kaiser Permanente, highlighting the organization’s experience using the survey during its field-testing phase. Speakers: Jonathan Bakdash, Ph.D., Agency for Healthcare Research and Quality Rebecca Anhang-Price, Ph.D., RAND Melissa Bradley, RAND Susan Wang, MD, Kaiser Permanente Stephanie Fry, CPXP, (Moderator), Westat https://www.ahrq.gov/cahps/surveys-guidance/end-of-life/index.html

Expanded Access to Investigational Drugs for Treatment Use - Questions and Answers April 15, 2026 | 1:00 PM - 2:30 PM ET

Expanded Access to Investigational Drugs for Treatment Use - Questions and Answers April 15, 2026 https://www.fda.gov/drugs/news-events-human-drugs/expanded-access-investigational-drugs-treatment-use-questions-and-answers-04152026?utm_medium=email&utm_source=govdelivery Join the Small Business and Industry Assistance (SBIA) program for an informative webinar on the guidance, Expanded Access to Investigational Drugs for Treatment Use: Questions and Answers. Expanded access is a pathway for patients with serious or immediately life-threatening diseases or conditions to gain access to investigational drugs for treatment outside of clinical trials when no comparable or satisfactory alternative treatment options are available. The primary goal of this event is to provide attendees with a comprehensive understanding of this pathway, including the regulatory requirements and FDA’s recommendations. The session will detail the three categories of Expanded Access (EA): individual patient, intermediate-size population, and treatment INDs and protocols, and will increase participants’ understanding of the criteria, submission requirements, and responsibilities of all parties involved. Expanded Access to Investigational Drugs for Treatment Use: Questions and Answers October 2025 https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expanded-access-investigational-drugs-treatment-use-questions-and-answers-0?utm_medium=email&utm_source=govdelivery